Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | MVD | P53602 | 2/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11952594 | 0.89 | SAT1 (0.38) | BTN3A1MVDSAT1 | |
| SCHEMBL26334838 | 0.83 | CA2 (0.38) | BTN3A1P2RY14P2RY6CA2CA9 | |
| SCHEMBL11952574 | 0.81 | BTN3A1 (0.38) | BTN3A1P2RY14MVDSAT1 | |
| SCHEMBL11952601 | 0.80 | ACHE (0.41) | BTN3A1SAT1 | |
| SCHEMBL28583404 | 0.74 | — | — | |
| SCHEMBL91094 | 0.74 | BTN3A1 (0.41) | BTN3A1MVDSAT1 | |
| Pent-4-Ynyl Diphosphate SCHEMBL1652909 | 0.73 | BTN3A1 (0.46) | BTN3A1P2RY6MVD | |
| SCHEMBL11952605 | 0.72 | SAT1 (0.42) | BTN3A1MVDSAT1 | |
| SCHEMBL14816068 | 0.72 | BTN3A1 (0.44) | BTN3A1P2RY6MVD | |
| SCHEMBL23118552 | 0.71 | SAT1 (0.41) | BTN3A1MVDSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | BTN3A1 4124/4885P2RY14 4322/4885P2RY6 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.